DWMG
NVCR icon

DB Wealth Management Group’s NovoCure NVCR Stock Holding History

DB Wealth Management Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed -$10K – 361
2021
Q3 		$12K Hold
100
– – 0.01% 256
2021
Q2 		$22K Hold
100
– – 0.01% 221
2021
Q1 		$13K Hold
100
– – 0.01% 257
2020
Q4 		$17K Buy
+100
New +$13.7K 0.01% 238

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DB Wealth Management Group's NVCR Position: Q4 2021 in Review

DB Wealth Management Group sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 100 shares — an estimated $10K sold.

DB Wealth Management Group first reported a position in NVCR in Q4 2020 and held it in 4 quarters. The position peaked at $22K in Q2 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

  • DB Wealth Management Group reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
  • DB Wealth Management Group sold 100 NovoCure shares in Q4 2021, an estimated $10K.
  • DB Wealth Management Group first reported a position in NovoCure in Q4 2020 and held it in 4 quarters.
  • DB Wealth Management Group's NovoCure position peaked at $22K in Q2 2021.
  • 311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on DB Wealth Management Group's 13F filing for Q4 2021, filed 9 Feb 2022.